Participants receiving a histologic diagnosis of epithelial ovarian cancer (EOC), peritoneal primary carcinoma, or fallopian tube cancerXx_NEWLINE_xXReceived a current diagnosis of borderline epithelial ovarian tumor (formerly tumors of low malignant potential)Xx_NEWLINE_xXHave recurrent invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer that was treated only with surgery (example [e.g.], participants with Stage IA or Stage IB epithelial ovarian or fallopian tube cancers)Xx_NEWLINE_xXReceived prior chemotherapy for any abdominal or pelvic tumor that include neoadjuvant chemotherapy (NACT) for ovarian, primary peritoneal or fallopian tube cancerXx_NEWLINE_xXReceived any biological and/or targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management and/or treatment of epithelial ovarian or peritoneal primary cancerXx_NEWLINE_xXHigh grade ovarian cancer, including high grade serous; clear cell; endometrioid, grade 3; and others (adenocarcinoma, nitric oxide synthase [NOS]; mixed epithelial carcinoma; undifferentiated carcinoma); NOTE: low grade serous, mucinous and carcinosarcoma histologies are excluded; ovarian cancer = ovarian, fallopian tube or primary peritoneal cancer; required data element: submission of pathology reportXx_NEWLINE_xXThe study population will include women with a high preoperative suspicion of advanced primary epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (stage IIIC or IV) as determined by computed tomography (CT) or magnetic resonance imaging (MRI) of abdomen and pelvis planning to undergo exploratory laparotomy and surgical cytoreduction with the operative goal of this procedure to achieve optimal cytoreduction to less than 1 cm of residual diseaseXx_NEWLINE_xXCohort A Dose Expansion (Ribociclib + PDR001): Metastatic epithelial ovarian cancer, fallopian tube or peritoneal cancer; all histologies (including serous, mucinous, endometrioid, clear cell, MMMTs and mixed histologies) and tumor grades are eligibleXx_NEWLINE_xXOvarian cancerXx_NEWLINE_xXPlatinum resistant Grade 2 or 3 ovarian, primary peritoneal or fallopian tube cancerXx_NEWLINE_xXPatients must have a histological or cytological evidence/confirmation of epithelial ovarian cancer, primary peritoneal carcinomatosis, or fallopian tube cancerXx_NEWLINE_xXHave a histologically confirmed diagnosis of high-grade serous or Grade 2 or Grade 3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancerXx_NEWLINE_xXHistologic confirmation of ovarian, primary peritoneal or fallopian tube cancer of any subtypeXx_NEWLINE_xXPatient with primary or recurrent International Federation of Gynecology and Obstetrics (FIGO) stage III or IV ovarian, fallopian tube, peritoneal carcinoma, or uterine cancer, confined to abdominal cavity, including those who have completed neoadjuvant chemotherapy and primary surgeryXx_NEWLINE_xXPreoperative or intraoperative (frozen section) diagnosis of ovarian, peritoneal, fallopian tubal or uterine cancerXx_NEWLINE_xXPatients must have recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma; histologic documentation of the original primary tumor is required via the pathology report; the following histologic epithelial cell types are eligible:\r\n* Serous, endometrioid, mucinous, or clear cell adenocarcinoma\r\n* Undifferentiated, mixed epithelial or transitional cell carcinoma\r\n* Brenner’s tumor\r\n* Adenocarcinoma not otherwise specified (N.O.S)Xx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXPatients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer or localized breast cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXHave a diagnosis of advanced platinum resistant epithelial ovarian cancer (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC) • Up to 2-3 prior lines of therapyXx_NEWLINE_xXWomen who have high-grade serous ovarian, primary peritoneal or fallopian tube cancer.Xx_NEWLINE_xXHistologically or cytologically confirmed advanced ovarian cancer: epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer (excluding borderline ovarian cancer) that is resistant or refractory to platinum therapy and no other standard therapy with proven clinical benefit is available.Xx_NEWLINE_xXHistological diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer, excluding the mucinous subtype.Xx_NEWLINE_xXPart 2, Cohorts 1-3, all patients must have a histologically-confirmed diagnosis of high grade serous ovarian cancer (including fallopian tube cancer and/or primary peritoneal cancer)Xx_NEWLINE_xXPatient with Colorectal cancer, epithelial ovarian cell or fallopian tube carcinoma, urothelial carcinoma, Triple Negative Breast cancer, pancreatic cancer, AML/MDS or Multiple MyelomaXx_NEWLINE_xXPatients must have histologically confirmed high grade serous ovarian or primary peritoneal or fallopian tube cancer; platinum resistant disease is defined as progression within 6 months after last platinum regimenXx_NEWLINE_xXPatients must have clinically and radiographically suspected and previously untreated International Federation of Gynecologic and Obstetrics (FIGO) stage III or IV epithelial ovarian, primary peritoneal or fallopian tube cancer, high grade, for whom the plan of management will include neoadjuvant chemotherapy (NACT) with interval tumor reductive surgery (TRS) who have undergone biopsies for histologic confirmationXx_NEWLINE_xXPatients who have received any targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their epithelial ovarian, fallopian tube or peritoneal primary cancerXx_NEWLINE_xXSubjects with peritoneal disease who have failed prior standard chemotherapy and have histologic confirmation of platinum-resistant or refractory epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, endometrial cancer, cervical cancer, vaginal and vulvar cancer, uterine sarcomas including leiomyosarcoma, carcinosarcoma or high grade endometrial stromal sarcoma, gastroesophageal cancer, pancreatic cancer, cholangiocarcinoma, colorectal cancer, gastrointestinal neuroendocrine tumors, or mesothelioma will be enrolled.Xx_NEWLINE_xXHistologically or cytologically-confirmed recurrent or resistant (progression within 6 months following the last administered platinum based therapy or progression after subsequent therapy in previously relapsed subjects), stage III-IV epithelial ovarian, fallopian tube or peritoneal cancer subjects (according to American Joint Committee on Cancer/Union for International Cancer Control TNM and International Federation of Gynecology and Obstetrics Staging System, 7th edition) whose disease has progressed following adjuvant therapy or therapy for metastatic disease.Xx_NEWLINE_xXHistologically confirmed stage IIc-IV epithelial ovarian, fallopian tube or peritoneal cancerXx_NEWLINE_xXFor Part 2 Only: Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, or Triple Negative Breast Cancer with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in at least 1 lesion, that in the opinion of the Investigator is appropriate to treat with nab-paclitaxel.Xx_NEWLINE_xXEpithelial ovarian carcinoma (including primary peritoneal disease and/or fallopian tube carcinomas and/or endometrial adenocarcinomas) regardless of platinum sensitivity.Xx_NEWLINE_xXPart 1: Ovarian, fallopian tube, primary peritoneal, endometrial, or cervical cancerXx_NEWLINE_xXRecurrent, persistent, or progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer after treatment with bilateral oophorectomy and either cisplatin or carboplatin and either paclitaxel, albumin-bound paclitaxel, or docetaxel; histologic confirmation of the primary tumor is required; eligible histologies include serous, endometrioid, clear cell, mucinous, transitional cell, undifferentiated, or mixed carcinomaXx_NEWLINE_xXMeasurable disease by physical exam or CT scan, or evaluable disease by CA-125; (NOTE: CA-125-evaluable disease is defined as serum CA-125 >= 2 x ULN that is determined by the treating clinician to be due to recurrent ovarian, fallopian tube, or primary peritoneal cancer)Xx_NEWLINE_xXPatients enrolling in the sporadic high grade serous epithelial or high grade endometrioid ovarian cancer group, cohort 2, must have a negative family history of hereditary breast ovarian cancer (HBOC) syndrome, or negative gBRCA1/2m testXx_NEWLINE_xXFor cohorts 1-3, 5 and 6: patients must have breast and/or epithelial or endometrioid ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer histologically or cytologically confirmed at the National Cancer Institute (NCI) that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective; ER/PR/HER2 status needs to be documented either by an outside source or at NCI; patients with gBRCA1/2m with history of or active breast and ovarian cancers are considered for cohort 1; those without gBRCA1/2m will follow exclusion criteriaXx_NEWLINE_xXEligible patients will be women with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma after chemotherapy with no evidence of disease or minimal residual disease for primary or recurrent disease; this may or may not be measurable; these patients would normally enter a period of observation after standard managementXx_NEWLINE_xXPatients must have histologically or cytologically confirmed high grade serous or high grade endometrioid ovarian, fallopian tube, primary peritoneal cancerXx_NEWLINE_xXPatients must have histologically or cytologically confirmed:\r\n* Recurrent endometrial cancer (all histologies, including carcinosarcoma)\r\n* Recurrent ovarian, primary peritoneal (female only), or fallopian tube cancer\r\n** all histologies except low grade serous or clear cell carcinoma unless the patient has a known\r\nsomatic or germline breast cancer (BRCA) mutation disease that is metastatic and for which standard curative\r\nmeasures do not exist or are no longer effectiveXx_NEWLINE_xXFor the dose expansion cohort, patients with recurrent endometrial cancer, recurrent BRCA mutated ovarian cancer (except first-recurrence platinum sensitive ovarian cancer), and platinum resistant ovarian cancer are eligibleXx_NEWLINE_xXPatients with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer must have received at least one platinum-based chemotherapy regimenXx_NEWLINE_xXOvarian cancer of serous histologyXx_NEWLINE_xXSTUDY ENTRY: No prior treatment for primary advanced (stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.Xx_NEWLINE_xXSTUDY TREATMENT: Histology consistent with high-grade epithelial ovarian cancer (excluding mucinous carcinoma, clear cell carcinoma, and carcinosarcoma).Xx_NEWLINE_xXGENERAL: Prior systemic chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer.Xx_NEWLINE_xXOvarian Expansion Cohort: Subjects with recurrent disease or histologically or cytologically confirmed Stage III/IV diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma who have previously progressed while receiving or within 6 months of completing a platinum-containing regimen.Xx_NEWLINE_xXSubjects must have histologically or cytologically confirmed advanced epithelial ovarian, fallopian tube, or primary peritoneal (>= International Federation of Gynecology and Obstetrics [FIGO] Stage IIIC)Xx_NEWLINE_xXDiagnosis of primary ovarian cancer of any histology (patients with diagnoses of fallopian tube and primary peritoneal cancer are also eligible), or primary uterine cancer of papillary serous histologyXx_NEWLINE_xXPatients with a histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, stage IIIB – IIIC with optimal (=< 1 cm) residual diseaseXx_NEWLINE_xXPatients with a current diagnosis of borderline epithelial ovarian tumor (formerly “tumors of low malignant potential”) or recurrent invasive epithelial ovarian cancer treated with surgery only (such as those with stage Ia or Ib low grade lesions) are not eligible; patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated, new invasive epithelial ovarian or peritoneal primary cancer are eligible, provided that they have not received prior chemotherapy for any ovarian tumorXx_NEWLINE_xXHistologic diagnosis of recurrent epithelial ovarian, fallopian, peritoneal cancerXx_NEWLINE_xXPatients with platinum resistant ovarian cancer must have progressed through at least one prior chemotherapy regimen for recurrent ovarian cancerXx_NEWLINE_xXPlatinum-refractory ovarian, fallopian tube, or primary peritoneal carcinomaXx_NEWLINE_xXPatients must have histologically or cytologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma; histologic documentation (via the pathology report) of the original primary tumor is requiredXx_NEWLINE_xXPatients must have clinically and radiographically suspected International Federation of Gynecology and Obstetrics (FIGO) stage 3 or 4 epithelial ovarian, primary peritoneal or fallopian tube cancer, high grade, for whom the plan of management will include neoadjuvant chemotherapy (NACT) with interval tumor reductive surgery (TRS); patients will be selected for NACT according to established criteria (Society of Gynecologic Oncology and the American Society of Clinical Oncology Guideline); patients must have undergone core needle biopsy for histologic confirmation prior to start of treatmentXx_NEWLINE_xXPatients who have received any prior treatment for management of their epithelial ovarian, fallopian tube or peritoneal primary cancerXx_NEWLINE_xXMust have a histological diagnosis of epithelial adenocarcinoma of ovarian, tubal or peritoneal origin that is persistent or progressive following multiple rounds of prior standard of care and experimental therapy.Xx_NEWLINE_xXOriginal diagnosis and/or histological confirmation of high-grade serous, high-grade endometrioid, undifferentiated/unclassifiable epithelial ovarian, fallopian tube or primary peritoneal cancer.Xx_NEWLINE_xXPatients with newly diagnosed advanced stage (III/IV) ovarian cancer (ovarian/fallopian tube/peritoneal cancer) who have been recommended to receive neoadjuvant carboplatin/paclitaxel chemotherapy with subsequent cytoreductive surgeryXx_NEWLINE_xXHistology (reviewed at MD Anderson Cancer Center [MDACC]) showing recurrent high grade epithelial ovarian, peritoneal, or fallopian tube cancer.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed advanced metastatic or unresectable epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer that is relapsed and resistant (recurred less than 6 months after chemotherapy) or refractory (progressed on chemotherapy) to prior platinum- and taxane-based standard care systemic regimen; or patients who are not eligible for additional platinum therapy; histopathologic diagnosis must be confirmed in the laboratory of pathology (LP), National Cancer Institute (NCI)Xx_NEWLINE_xXHistologically confirmed stage III-IV high-grade epithelial non-mucinous ovarian, fallopian tube, or primary peritoneal cancersXx_NEWLINE_xXHistology showing mucinous or low-grade epithelial ovarian carcinomaXx_NEWLINE_xXParticipant may have serous, endometrioid, clear cell, mucinous or undifferentiated type of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer\r\n* Histologic confirmation of the original primary tumor is required via the pathology reportXx_NEWLINE_xXPatients must have histologically confirmed endometrial cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer (all histologic subtypes)Xx_NEWLINE_xXHave histologically or cytologically confirmed gynecologic tumor of mullerian origin, specifically epithelial ovarian, fallopian tube, primary peritoneal, or uterine endometrial cancerXx_NEWLINE_xXHistology showing high-grade epithelial non-mucinous ovarian, primary peritoneal, or fallopian tube cancerXx_NEWLINE_xXNo prior treatment for primary advanced (stage III or IV) epithelial ovarian, primary peritoneal, or fallopian tube carcinoma such as irradiation, chemotherapy, hormonal therapy, immunotherapy, investigational therapy, surgery, and/or other concurrent agents or therapiesXx_NEWLINE_xXPrior treatment for ovarian, fallopian tube, or primary peritoneal cancerXx_NEWLINE_xXA histologically confirmed diagnosis of high-grade serous epithelial ovarian cancer including primary peritoneal and fallopian tube malignancies; all other histologies, including mixed histology, are excludedXx_NEWLINE_xXPatients with histologic diagnosis of epithelial ovarian carcinoma, primary peritoneal carcinoma, or fallopian tube carcinoma that has recurred > 6 months since platinum-based chemotherapy (first recurrence) and who are scheduled for secondary surgical evaluation/cytoreductionXx_NEWLINE_xXPathologically confirmed diagnosis of high-grade serous ovarian, primary peritoneal, or fallopian tube carcinomaXx_NEWLINE_xXPatients must have had one prior platinum-based chemotherapeutic regimen for management of ovarian, primary peritoneal, or fallopian tube carcinoma and at least two prior chemotherapy regimensXx_NEWLINE_xXPatients must have recurrent or persistent EOC (epithelial ovarian, fallopian tube or primary peritoneal carcinoma); histologic documentation of the original primary tumor is required via the pathology reportXx_NEWLINE_xXHistology consistent with primary peritoneal mesothelioma rather than primary peritoneal serous carcinomaXx_NEWLINE_xXPHASE II STUDY COHORT 1 OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C): MEDI+O+C: Patients must have histologically or cytologically confirmed persistent or recurrent non-mucinous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are either platinum-sensitive, platinum resistant or refractory during or after a first platinum containing regimen; for platinum-sensitive recurrent serous epithelial ovarian cancer, the patients must have received at least two prior regimens prior to study enrollmentXx_NEWLINE_xXSubject has primary ovarian (including low malignant potential), fallopian tube, or primary peritoneal cancer Federation of Gynecology and Obstetrics (FIGO) stage III or IV defined surgically at the completion of initial abdominal surgeryXx_NEWLINE_xXPatients must have peritoneal recurrence of epithelial adenocarcinoma or carcinosarcoma of ovarian, tubal, or peritoneal origin; histologic documentation of the original primary tumor is required via the pathology report; original tumor blocks from primary diagnosis will be reviewed by our study pathologist at MageeXx_NEWLINE_xXPatients with tumors of low malignant potential, except ovarian pseudomyxoma or with no peritoneal diseaseXx_NEWLINE_xXPatients must have histologically or cytologically confirmed, known or highly suspected advanced (International Federation of Gynecology and Obstetrics [FIGO] stage II-IV) ovarian, primary peritoneal, or fallopian tube cancer, scheduled for primary or interval cytoreductive surgeryXx_NEWLINE_xXPatients for whom the diagnosis of high-grade serous or undifferentiated carcinoma of ovarian, peritoneal, or fallopian tubal origin is confirmed at surgeryXx_NEWLINE_xXRecurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma; histologic confirmation of the original primary tumor is requiredXx_NEWLINE_xXPatients must have received at least one-prior platinum based chemotherapy regimen, to include cisplatin, carboplatin or other organoplatinum compound, for treatment of primary or recurrent ovarian, fallopian tube or primary peritoneal cancerXx_NEWLINE_xXMust have:\r\n* Recurrent or progressive ovarian cancer, primary peritoneal cancer or fallopian tube cancer after prior treatment with platinum and taxanes\r\n* Histologic confirmation of the original primary tumor\r\n* Prior bilateral oophorectomyXx_NEWLINE_xXELIGIBILITY CRITERIA FOR REGISTRATION: subjects must have histologically confirmed carcinoma consistent with ovarian, fallopian tube, or primary peritoneal carcinoma (any of these three are referred to in this protocol as “ovarian cancer [OvCA]” OR a cytological diagnosis of carcinoma); the following histologic subtypes are included: serous, endometrioid, undifferentiated, clear cell, mixed, transitional, malignant Brenner tumor or adenocarcinoma not otherwise specified (NOS); subjects eligible for this study may be in one of three surgical categories: status post primary debulking surgery; undergoing neoadjuvant chemotherapy at a site not participating in correlative tissue collection sub study OR undergoing neoadjuvant chemotherapy at a site participating in correlative tissue collection sub studyXx_NEWLINE_xXHistologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinomaXx_NEWLINE_xXPatients with histologically or cytologically confirmed diagnosis of advanced, epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer who have all of the following:Xx_NEWLINE_xXNewly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Xx_NEWLINE_xXParticipants must have histologically or cytologically confirmed endometrial, ovarian (including ovarian, fallopian tube, primary peritoneal), cervical, vaginal, or vulvar cancer that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXDiagnosis of Federation of Gynecology and Obstetrics (FIGO) stage III or grade IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma, has received at least 3 cycles of first line intravenous (IV)/IP cisplatin and paclitaxel chemotherapy and has stable disease or better as defined by measurable/evaluable tumor and/or CA-125 levelsXx_NEWLINE_xXSubjects with locally invasive or metastatic, epithelial ovarian, fallopian tube, or primary peritoneal cancerXx_NEWLINE_xXSubjects with low-grade ovarian, fallopian tube, or Primary peritoneal cancerXx_NEWLINE_xXHistologically confirmed recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer for which there is no known or established treatment available with curative intent.Xx_NEWLINE_xXPatients with clinical or surgical stage III or IV low-grade serous ovarian, primary peritoneal, or fallopian tube carcinomas who in the judgement of the treating physician are unlikely to achieve optimal surgical cytoreduction and have been recommended to receive neoadjuvant therapy.Xx_NEWLINE_xXPatients with biopsy-confirmed ovarian or other gynecologic cancers (fallopian tube, peritoneal, endometrial, or cervical cancer) who have recurred after or progressed on frontline and one or more second-line standard treatments are eligible for the dose-finding phase; enrollment for the expansion cohort will be limited to subjects with high grade epithelial ovarian, fallopian tube, or peritoneal carcinomasXx_NEWLINE_xXPatients with low grade ovarian/fallopian tube/peritoneal cancersXx_NEWLINE_xXHistopathologic documentation (must be performed or reviewed at MD Anderson) of recurrent high grade epithelial ovarian cancer.Xx_NEWLINE_xXHistology showing recurrent high grade epithelial ovarian, peritoneal, or fallopian tube cancerXx_NEWLINE_xXChemotherapy, hormonal, or biologic treatment for ovarian, fallopian tube, or primary peritoneal cancer in the last 21 daysXx_NEWLINE_xXThe participant must have a histologic diagnosis of recurrent high grade serous ovarian cancer (ovarian, tubal, peritoneal), to be treated with chemotherapyXx_NEWLINE_xXWomen with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with platinum-resistant disease (defined as having relapsed within 6 months of last platinum-containing regimen because we would like to include both primary and secondary resistance); patients are allowed to have had more than 2 prior cytotoxic treatment regimens; all patients should have received standard of care agents, which confer clinical benefitXx_NEWLINE_xXPHASE II: All patients enrolled in the Phase II portion of this trial must have a history of biopsy-proven ovarian, fallopian tube or primary peritoneal cancerXx_NEWLINE_xXParticipants must have recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma; histologic documentation of the original primary tumor is required via the pathology reportXx_NEWLINE_xXPatients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXDiagnosis of recurrent epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer that has failed or progressed after at least 1 prior salvage chemotherapy regimen directed at recurrent/metastatic diseaseXx_NEWLINE_xXGynecologic cancer cohort only: histologic proof of epithelial cervical, endometrial, ovarian, fallopian, or primary peritoneal cancers; allowable histologies for cervical cancer include squamous cell carcinoma, adenocarcinoma, and mixed/adenosquamous carcinoma; allowable histologies for endometrial cancer include endometrioid, serous, clear cell, mucinous, squamous, transitional cell, undifferentiated, mixed, and carcinosarcoma (this is considered a poorly differentiated epithelial tumor); allowable histologies for ovarian, fallopian, and peritoneal cancer include serous, clear cell, endometrioid, mucinous, transitional cell, undifferentiated, mixed, and carcinosarcomaXx_NEWLINE_xXPatients with histologically proven stage III or IV ovarian, fallopian tube or primary peritoneal serous carcinoma (or patients of any stage with recurrent disease) who demonstrate lack of disease progression as determined by clinical assessment as well as cancer antigen 125 (CA-125) levels and/or radiographic assessmentXx_NEWLINE_xXPatients who have undergone therapeutic debulking surgery for independent clinical indications and have tissue frozen and stored under sterile conditions as part of protocol 07-319 (Study of Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer)Xx_NEWLINE_xXParticipants must have pathology-confirmed epithelial ovarian, fallopian tube, or\n             primary peritoneal carcinoma.Xx_NEWLINE_xXParticipants with histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or fallopian tube cancer will be enrolled in this study; patients must have experienced recurrence or progression within 6 months after completion of platinum based chemotherapy (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria).Xx_NEWLINE_xXParticipants must have histologically or cytologically confirmed diagnosis of either:\r\n* Ovarian, fallopian tube, or primary peritoneal cancer of high grade serous histology which has recurred despite standard therapy or\r\n* Triple-negative breast cancer which has recurred despite standard therapyXx_NEWLINE_xXSolid tumor patients in stage 2 must have a diagnosis of papillary serous, endometrioid or clear cell endometrial carcinoma or, high grade serous, clear cell, endometrioid or mucinous ovarian, fallopian or primary peritoneal carcinomaXx_NEWLINE_xXNewly diagnosed stage III or IV epithelial ovarian, fallopian or primary peritoneal carcinoma with or without ascites and potentially resectable disease agreeing to debulking surgery as standard therapyXx_NEWLINE_xXPatients who have had prior systemic therapy or radiotherapy for stage III or IV epithelial ovarian, fallopian or primary peritoneal carcinomaXx_NEWLINE_xXPatients with a histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, or carcinosarcoma stage II, III, or IV with either optimal (=< 1 cm residual disease) or suboptimal residual diseaseXx_NEWLINE_xXAll patients must have a procedure for determining diagnosis of epithelial ovarian, fallopian tube, primary peritoneal, or carcinosarcoma with appropriate tissue for histologic evaluationXx_NEWLINE_xXPatients with a current diagnosis of borderline epithelial ovarian tumor (formerly “tumors of low malignant potential”) or recurrent invasive epithelial ovarian, primary peritoneal or fallopian tube cancer treated with surgery only (such as patients with stage IA or IB low-grade epithelial ovarian or fallopian tube cancers) are not eligible\r\n* NOTE: Patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated, new invasive epithelial ovarian, peritoneal primary or fallopian tube cancer are eligible, provided that they have not received prior chemotherapy for any ovarian tumorXx_NEWLINE_xXHistologic diagnosis of International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, with the appropriate tissue available for histologic evaluation.Xx_NEWLINE_xXDiagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancerXx_NEWLINE_xXPatients must have histologic diagnosis of epithelial ovarian carcinoma, peritoneal primary or fallopian tube carcinoma, which is now recurrentXx_NEWLINE_xXPatients with a prior histologic diagnosis of borderline, low malignant potential (grade 0) epithelial carcinoma that was surgically resected and who subsequently developed an unrelated, new invasive epithelial ovarian or peritoneal primary cancer are eligible provided that they meet the criteria listed aboveXx_NEWLINE_xXPatients who have received prior chemotherapy for any abdominal or pelvic tumor (other than ovarian, fallopian tube, and primary peritoneal) are excludedXx_NEWLINE_xXPatient must have histologically confirmed, advanced (FIGO Stage III or IV) high-grade predominantly serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have completed first line platinum based chemotherapy (neoadjuvant or adjuvant)Xx_NEWLINE_xXPatient has mucinous or clear cell subtypes of epithelial ovarian cancer, carcinosarcoma or undifferentiated ovarian cancerXx_NEWLINE_xX1b. Ovarian Recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma requiring original or subsequent relapse histologic documentation. A platinum-taxane based chemotherapy regimen as frontline therapy must have been completed. Any histologic diagnosis of borderline, low malignant potential epithelial carcinoma are excluded.Xx_NEWLINE_xXPhase 2 expansion: Ovarian cancerXx_NEWLINE_xXPatients must have recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma; histologic documentation of the original primary tumor is required via the pathology reportXx_NEWLINE_xXPatients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXHistologically confirmed Stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, including malignant mixed Müllerian tumors with high grade serous componentXx_NEWLINE_xXPatients must have histologically diagnosed high-grade (Grade 2 or 3) serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease and must have been previously treated with chemotherapy and experienced a response lasting at least 6 months to first-line platinum based therapy.Xx_NEWLINE_xXOvarian CancerXx_NEWLINE_xXHistologically confirmed epithelial ovarian, fallopian tube, or peritoneal cancer, including malignant mixed Müllerian tumors with high grade serous component.Xx_NEWLINE_xXTumor histology consistent with one of the following: In Part 1, Dose Escalation - melanoma, NSCLC, ovarian cancer (including fallopian tube carcinoma), or sarcoma (any subtype). In Part 2, Patient Expansion - NSCLC, ovarian cancer (including fallopian tube carcinoma), or the sarcoma subtypes, synovial sarcoma or myxoid/round cell liposarcomaXx_NEWLINE_xXPhase 1: Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinomas who are considered to have platinum-resistant disease (progression within 6 months from completion of platinum-based chemotherapy).Xx_NEWLINE_xXPhase 2: Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinomas who are considered to have platinum-resistant disease (progression within 6 months from completion of a minimum of 4 platinum therapy cycles).Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed epithelial ovarian, primary peritoneal and fallopian tube carcinoma; all histologic subtypes of epithelial ovarian cancer are eligible, but only patients with high grade serous ovarian cancer will be considered for the statistical analysis; non-high grade serous cancers will be allowed in an exploratory cohortXx_NEWLINE_xXHistologically proven advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancerXx_NEWLINE_xXDiagnosis of ovarian carcinoma with mucinous histologyXx_NEWLINE_xXPatients with recurrent epithelial ovarian cancer, fallopian tube cancers or primary peritoneal carcinoma defined as:Xx_NEWLINE_xXPatients must have received at least one prior salvage regimen for recurrent ovarian cancerXx_NEWLINE_xXPatients with histologically diagnosed relapsed high grade serous ovarian cancer (including primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer. Patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease >6 months (>/=183 days) after completion of their last platinum therapy.Xx_NEWLINE_xXPatients must have recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Histologic documentation of the original primary tumor is required via the pathology report.Xx_NEWLINE_xXPatients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers who have received up to two prior treatment regimensXx_NEWLINE_xXepithelial ovarian cancer (fallopian tube and primary peritoneal cancers are eligible)Xx_NEWLINE_xXHas histologically confirmed epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancerXx_NEWLINE_xXHas epithelial ovarian cancer (EOC) with mucinous histology subtypeXx_NEWLINE_xXPatients must have recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer with documented disease progression (disease not amendable to curative therapy); histologic confirmation of the original primary tumor is required via the pathology report; NOTE: patients with mucinous histology are NOT eligible; patients with carcinosarcoma histology are NOT eligibleXx_NEWLINE_xXOvarian cancer defined as a histologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer refractory to standard therapies of for which no standard therapy exists. Confirmed BRCA1 or BRCA2 mutation from a prior test. Patient progressed while receiving and/or following treatment with a PARP-inhibitor for advanced disease (recurrent or metastatic.Xx_NEWLINE_xXPersistent or recurrent serous epithelial ovarian cancer or primary peritoneal carcinomaXx_NEWLINE_xXConfirmed diagnosis of high-grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer.Xx_NEWLINE_xXOvarian CarcinomaXx_NEWLINE_xXThe patient must have a pathologically confirmed (by histology or cytology) diagnosis of epithelial ovarian, fallopian tube or primary peritoneal carcinoma, which is currently recurrent or persistent Stage 3 or Stage 4 disease. A histologic diagnosis of borderline, low malignant potential epithelial carcinoma is not permitted.Xx_NEWLINE_xXFemales aged ?18 years with previous histologically proven diagnosis of high grade serous, high grade endometroid or clear cell ovarian cancer, fallopian tube or primary peritoneal carcinomaXx_NEWLINE_xXParticipants must have histologic or cytologic confirmation of epithelial ovarian cancer, fallopian tube or peritoneal cancer; all histologies (including serous, mucinous, endometrioid, clear cell, malignant mixed mesodermal tumor [MMMTs], and mixed histologies) are eligible; all tumor grades are eligibleXx_NEWLINE_xXHave a histologically confirmed diagnosis of epithelial ovarian cancer, fallopian tube or peritoneal cancer; all histologies of epithelial ovarian cancer are eligible except for carcinosarcomasXx_NEWLINE_xXPathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed by pathology review at Memorial Sloan Kettering (MSK)Xx_NEWLINE_xXHistologically or cytologically confirmed primary disease histology of solid ovarian, fallopian tube, or primary peritoneal tumor categorizationXx_NEWLINE_xXHistologically confirmed ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.Xx_NEWLINE_xXPatients with histologically documented diagnosis of epithelial ovarian cancer including serous papillary, endometrioid, mucinous, clear cell, poorly differentiated or mixed adenocarcinomasXx_NEWLINE_xXPatient must have recurrent epithelial ovarian cancer and may have received unlimited prior chemotherapeutic regimens for management of recurrent cancerXx_NEWLINE_xXSymptomatic effusions due to pleural, pericardial, or peritoneal metastasis of epithelial ovarian cancerXx_NEWLINE_xXPatients must have histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma per pre-treatment biopsies by laparoscopy, or interventional radiology or CT guided core biopsy. Histologic documentation of the original primary tumor is required via the pathology report.Xx_NEWLINE_xXPatients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinomaXx_NEWLINE_xXMust have confirmation of the histologic diagnosis of high-grade (grade 2 or 3) epithelial, non-mucinous, non-borderline, ovarian, fallopian tube, or primary peritoneal carcinoma; may be based on original pathology report or review of original slidesXx_NEWLINE_xXPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXPatients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseXx_NEWLINE_xXConfirmed diagnosis of unresectable epithelial ovarian, fallopian tube or primary peritoneal cancer.Xx_NEWLINE_xXPatients must have Memorial Sloan-Kettering Cancer Center (MSKCC) pathologically confirmed diagnosis of one of the following tumor types: \r\n* Ovarian, fallopian tube or primary peritoneal cancer\r\n* Ovarian carcinosarcoma\r\n* Endometrial cancer\r\n* Endometrial carcinosarcomaXx_NEWLINE_xXAny histologically confirmed locally advanced recurrent endometrial adenocarcinoma (except for carcinosarcoma), recurrent high-grade serous ovarian/primary peritoneal/fallopian tube carcinoma, or deleterious BRCA mutant recurrent ovarian/primary peritoneal/fallopian tube cancer for whom no curative option is available will be eligible; any patient proven to have metastatic triple negative breast cancer, defined from standard pathologic assays as negative for estrogen receptor (ER) and progesterone receptor (PR) (< 10% tumor staining) will be eligibleXx_NEWLINE_xXSubjects with histologic diagnosis of epithelial ovarian carcinoma, primary peritoneal carcinoma, or fallopian tube carcinoma, following initial surgery; all subjects must have had appropriate surgery for ovarian, primary peritoneal, or fallopian tube carcinoma with appropriate tissue available for histologic evaluation to confirm diagnosis and stage; pathology must be verified at Memorial Sloan-Kettering Cancer Center; patients with initial cytoreduction surgery performed at outside hospitals will be eligible for this protocolXx_NEWLINE_xXSubjects with a current diagnosis of epithelial ovarian tumor of low malignant potential (borderline carcinomas) are not eligibleXx_NEWLINE_xXHistologically confirmed surgical diagnosis of stage IIIC or stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer; patients with stage III cancer must have had peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis; NOTE: Histologic confirmation of the primary tumor is required; eligible histologies include serous, endometrioid, clear cell, mucinous, transitional cell, undifferentiated, or mixed carcinomaXx_NEWLINE_xXEpithelial ovarian cancer of low malignant potential (borderline tumor)Xx_NEWLINE_xXPatients are eligible if they have the following: metastatic or unresectable breast cancer, recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerXx_NEWLINE_xXFemale patients with histologically diagnosed relapsed high grade serous ovarian cancer (including primary peritoneal and / or fallopian tube cancer) or high grade endometrioid cancer.Xx_NEWLINE_xXFemale patients with newly diagnosed, histologically confirmed, high risk advanced (FIGO stage III - IV) BRCA mutated high grade serous or high grade endometrioid ovarian cancer, primary peritoneal cancer and / or fallopian - tube cancer who have completed first line platinum based chemotherapy (intravenous or intraperitoneal).Xx_NEWLINE_xXPatients who have previously been diagnosed and treated for earlier stage ovarian, fallopian tube or primary peritoneal cancer.Xx_NEWLINE_xXPatients who have previously received chemotherapy for any abdominal or pelvic tumour, including treatment for prior diagnosis at an earlier stage for their ovarian, fallopian tube or primary peritoneal cancer. (Patients who have received prior adjuvant chemotherapy for localised breast cancer may be eligible, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease).Xx_NEWLINE_xXHistologically confirmed epithelial ovarian, primary peritoneal or fallopian tube malignancy that is metastatic and for which standard curative measures do not existXx_NEWLINE_xXHistologically confirmed epithelial ovarian, peritoneal, or fallopian tube cancer, and uterine papillary serous carcinomas (UPSC), and gynecologic malignant mixed müllerian tumors (MMMTs).Xx_NEWLINE_xXHave been diagnosed with ovarian, fallopian tube, or primary peritoneal cancerXx_NEWLINE_xXHave been previously treated with Gemcitabine for ovarian, fallopian tube or primary peritoneal cancerXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed invasive epithelial ovarian, tubal or primary peritoneal cancer; all histologies (including serous, mucinous, endometrioid, clear cell, malignant mixed mesodermal tumors [MMMTs] and mixed histologies) are eligibleXx_NEWLINE_xXMust have a diagnosis of recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with refractory or platinum resistant disease and/or have received ? 2 lines of chemotherapyXx_NEWLINE_xXHistologically-confirmed ovarian epithelial (including fallopian tube and primary peritoneal) carcinomaXx_NEWLINE_xXPatients with biopsy proven stage IIIC/IV epithelial ovarian cancer, primary peritoneal, fallopian tube carcinoma; if a core biopsy is not possible, fine-needle aspirate showing adenocarcinoma is acceptable in the setting of a pelvic mass and presence of metastasis outside the pelvis measuring at least 2 cm, regional lymph-node metastasis or proof of stage IV disease, and ratio of cancer antigen (CA) 125 to carcinoembryonic antigen (CEA) greater than 25; if CA 125 to CEA ratio is 25 or lower, barium enema, gastroscopy, and mammography must be negativeXx_NEWLINE_xXPatients assumed to have a stageII?IV epithelial ovarian, fallopian tube, or primary peritoneal cancer as a pre-surgery diagnosisXx_NEWLINE_xXPatients assumed to have a borderline malignancy of the ovary, fallopian tube, or primary peritoneal cancerXx_NEWLINE_xXSuspected preoperative diagnosis of invasive epithelial ovarian cancer, primary peritoneal carcinoma, fallopian tube cancer based on imaging and cancer antigen (Ca) 125; histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell carcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise specified; patients with primarily carcinoma histology but mixed features can be included; the surgically confirmed histologic features must be compatible with primary Mullerian epithelial adenocarcinomaXx_NEWLINE_xXPatients who receive neoadjuvant chemotherapy for their ovarian, primary peritoneal, or fallopian tube cancerXx_NEWLINE_xXPatients with non-epithelial ovarian tumors that do not require adjuvant chemotherapy, borderline epithelial ovarian tumor, or recurrent invasive epithelial ovarian, low grade ovarian cancer, primary peritoneal, or fallopian tube cancer treated with surgery only (such as patients with stage IA or IB); patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated new invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer are eligible, provided that they have not received chemotherapy for any tumor; no stromal cancers or germ cell cancers or low malignant potential; patients found post operatively to have ineligible histology will be removed from the studyXx_NEWLINE_xXPatients who have received targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their primary peritoneal, ovarian, or fallopian tube cancerXx_NEWLINE_xXMetastases to the ovaries from other organs except fallopian tube or primary peritoneal carcinomaXx_NEWLINE_xXHave a histologically confirmed diagnosis of high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancerXx_NEWLINE_xXMemorial Sloan Kettering Cancer Center (MSKCC) histologically confirmed ovarian, fallopian tube or primary peritoneal carcinomaXx_NEWLINE_xXSubject has recurrent ovarian (including low malignant potential), fallopian tube or primary peritoneal cancerXx_NEWLINE_xXPHASE I: Participants must have histologically or cytologically confirmed epithelial ovarian cancer, primary peritoneal serous cancer, fallopian tube cancer, or triple-negative breast cancerXx_NEWLINE_xXPHASE II: Participants must have histologically or cytologically grade 2 or 3 (high-grade) papillary-serous or endometrioid epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancer; participants with epithelial ovarian, primary peritoneal, or fallopian tube cancers of other high-grade histologies who carry a known deleterious breast cancer gene (BRCA) germline mutation by standard clinical testing (Myriad BRAC Analysis) will also be considered eligibleXx_NEWLINE_xXPHASE I-T: Participants must have histologically or cytologically confirmed epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancerXx_NEWLINE_xXPRIOR THERAPY PHASE I and PHASE I-T:\r\n* Prior chemotherapy for ovarian cancer patients must have included a first-line platinum-based regimen with or without intravenous consolidation chemotherapy\r\n* Breast cancer patients must have recurred post both an Adriamycin- and taxane-containing regimen\r\n* Prior hormonal-based therapy for ovarian, primary peritoneal serous, fallopian tube cancer, or breast cancer is acceptable\r\n* Patients may not have had a prior PAR polymerase (PARP)-inhibitor in the recurrent or metastatic setting; prior treatment with BSI-201 (iniparib) is allowed\r\n* Patients may not have had a prior anti-angiogenic agent in the recurrent or metastatic settingXx_NEWLINE_xXPatients with a histologic diagnosis of epithelial ovarian cancer, peritoneal primary carcinoma or fallopian tube cancer; FIGO stage III and IV defined surgically at the completion of initial abdominal surgery and with appropriate tissue available for histologic evaluation. The minimum surgery required is an abdominal surgery providing tissue for histologic evaluation and establishing and documenting the primary site and stage, as well as a maximal effort at tumor debulking.Xx_NEWLINE_xXPatients with borderline epithelial ovarian tumor (formerly \tumors of low malignant potential\) or recurrent invasive epithelial ovarian, primary peritoneal or fallopian tube cancer treated with surgery only are not eligible. Patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated, new invasive epithelial ovarian, peritoneal primary or fallopian tube cancer are eligible, provided that they have not received prior chemotherapy for any ovarian tumor.Xx_NEWLINE_xXPatients who have received any targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their epithelial ovarian or peritoneal primary cancer.Xx_NEWLINE_xXHistopathologic diagnosis of ovarian cancer (including primary peritoneal and fallopian tube cancers) must be confirmed in the Laboratory of Pathology, National Cancer Institute (NCI)Xx_NEWLINE_xXPatient must have persistent or recurrent high grade endometrioid or serous ovarian, primary peritoneal or fallopian tube carcinoma; histologic documentation of the original primary tumor is required via the pathology reportXx_NEWLINE_xXHistologically documented, epithelial ovarian, fallopian tube, or primary peritoneal, high grade serous or clear cell carcinoma are eligible; all patients must have a confirmed pathology; stage 3 and 4 initial disease with response to primary surgery and neo/adjuvant chemotherapy, platinum refractory disease, and patients with recurrent disease are candidatesXx_NEWLINE_xXWomen with suspected epithelial ovarian, fallopian tube or primary peritoneal carcinoma scheduled to undergo surgical exploration with no prior treatment for the cancer; signs of ovarian cancer include, but are not limited to: an elevated CA125, a complex pelvic mass, ascites, and carcinomatosis; these signs are not necessary for suspicion or enrollment in this protocolXx_NEWLINE_xXDiagnosis of recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer; histologic or cytologic confirmation of the original primary tumor is requiredXx_NEWLINE_xXHistologically or cytologically confirmed epithelial ovarian, fallopian tube, or peritoneal cancerXx_NEWLINE_xXNon-epithelial ovarian carcinomas or ovarian tumors with low malignant potential (i.e., borderline tumors)Xx_NEWLINE_xXHistologically documented ovarian, primary peritoneal or fallopian tube cancerXx_NEWLINE_xXNon-epithelial ovarian carcinoma, including malignant mixed Mullerian tumorsXx_NEWLINE_xXHistological documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancerXx_NEWLINE_xXHistologically diagnosed ovarian cancer, fallopian tube cancer or primary peritoneal cancerXx_NEWLINE_xXEpithelial ovarian cancer or gynecological cancerXx_NEWLINE_xXPart 3 (enrollment closed): advanced, metastatic or non-resectable epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer withXx_NEWLINE_xXHistologically confirmed serous epithelial ovarian cancer with peritoneal metastasesXx_NEWLINE_xXLess than 4 weeks since last treatment for ovarian cancerXx_NEWLINE_xXHistologically documented epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that is platinum sensitive.Xx_NEWLINE_xXPSOC (i.e., epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer) with documented radiographic progression or relapse within 6 to 18 months of most recent platinum-based chemotherapy.Xx_NEWLINE_xXPatients must have achieved a complete response (CR) or partial response (PR), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, following treatment for recurrent ovarian, fallopian tube, or peritoneal cancer; histological confirmation of the original primary tumor is requiredXx_NEWLINE_xXPatients must have a histologically-confirmed ovarian, fallopian, or peritoneal malignancy with a component of high-grade papillary serous carcinoma; (example: a patient with ovarian carcinosarcoma with a component of high-grade papillary serous carcinoma will be eligible)Xx_NEWLINE_xXSubjects must have cytologically or histologically confirmed ovarian, primary peritoneal or fallopian tube cancer.. In addition, subjects must have a tumor that is at least 1 cm in a single dimension and is radiographically apparent on CT, PET-CT or MRI (i.e., RECIST version 1.1 measurable disease).Xx_NEWLINE_xXNon-epithelial ovarian carcinoma, including malignant mixed Mullerian tumors.Xx_NEWLINE_xXThe female subject has a diagnosis of one of the following: a) low-grade serous ovarian or peritoneal carcinoma, or grade 1 serous ovarian or peritoneal carcinoma or well-differentiated serous ovarian or peritoneal carcinoma or b) serous borderline ovarian or peritoneal tumor, ovarian or peritoneal tumor of low-malignant potential, ovarian or peritoneal atypical proliferative serous tumor that recurs as low grade serous carcinoma or has invasive peritoneal implants.Xx_NEWLINE_xXPart 1 and 2: Histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective. Subjects must also 1) have a documented BRCA1 or BRCA2 mutation that is considered to be deleterious by the investigator, OR 2) have high grade serous ovarian, fallopian tube, or peritoneal cancer. Subjects with molecular features indicative of DNA repair defects (such as mutation in the Fanconi anemia pathway genes or methylation of the BRCA1 promoter) may be considered eligible for following discussion with the medical monitor. Part 3: Histologically or cytologically confirmed breast, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or unresectable and for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective. Platinum-resistant ovarian cancer is not permitted. Subjects must also 1) have a documented BRCA1 or BRCA2 mutation that is considered to be deleterious by the investigator and 2) have received 3 or fewer regimens of cytotoxic chemotherapy in the metastatic setting and 3) have evaluable disease as defined by RECIST 1.1 or GCIC-CA-125 criteria.Xx_NEWLINE_xXPatients must be suspected of having a diagnosis of ovarian, fallopian tube or primary peritoneal cancer with a planned cytoreductive surgeryXx_NEWLINE_xXBorderline ovarian cancer with ascitesXx_NEWLINE_xXHistologic diagnosis of epithelial ovarian, fallopian tube or primary peritoneal cancer on frozen section diagnosisXx_NEWLINE_xXNon-epithelial ovarian cancer or metastatic cancer to the ovariesXx_NEWLINE_xXBorderline ovarian cancer without ascitesXx_NEWLINE_xXAdvanced or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma; histologic documentation of the original primary tumor is required via the pathological reportXx_NEWLINE_xXPatients must have newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) Stage IIIB to IV epithelial ovarian, fallopian tube, or peritoneal cancer and have recovered from debulking surgery.Xx_NEWLINE_xXUp to 6 patients with histological or cytological documentation of advanced ovarian, fallopian tube, or primary peritoneal carcinoma with a history of progression or recurrence following at least one prior platinum and one taxane based chemotherapyXx_NEWLINE_xXCytologic or histologic diagnosis of a carcinoma felt by the investigator to be compatible with epithelial cancer of the ovary, fallopian tube, or primary peritoneumXx_NEWLINE_xXPatients with borderline ovarian tumors, recurrent epithelial ovarian or primary peritoneal cancer or non-epithelial ovarian cancer are not eligibleXx_NEWLINE_xXWomen with stages II-IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who have completed standard therapy for primary or recurrent disease (i.e., patients who would normally be observed); eligible patients may have asymptomatic residual measurable disease on physical examination and/or computed tomography (CT) scan, and/or may have an elevated cancer antigen 125 (CA-125); or may be in complete clinical remission after treatment for primary or recurrent disease; these patients would normally enter a period of observation after standard managementXx_NEWLINE_xXFor the dose expansion cohort, participants must have histologically or cytologically confirmed diagnosis of either: i) ovarian, fallopian tube, or primary peritoneal cancer of high grade serous histology which has recurred despite standard therapy or ii) triple-negative breast cancer which has recurred despite standard therapyXx_NEWLINE_xXWomen with of primary or recurrent diagnosis of ovarian, uterine, peritoneal, cervical or vulvar cancer with any of the following:\r\n* < 30 % projected 5 year survival based on histopathological stage\r\n* Non-pelvic recurrent malignancy\r\n* Persistent or progressive disease despite primary treatment with surgery, chemotherapy or\r\n* Palliative performance scale < 60Xx_NEWLINE_xXDiagnosis of stage III, IV or recurrent gynecologic malignancy (uterine, ovarian, cervical, vulvar, vaginal, fallopian tube, primary peritoneal)Xx_NEWLINE_xXWomen with a history of leukemia, ovarian cancer or a cancer that likely involve the ovaries at the time of ovarian tissue collectionXx_NEWLINE_xXDiagnosis of ovarian epithelial, fallopian tube, or primary peritoneal carcinoma\r\n* Stage II, III, or IV disease with optimal (=< 1 cm residual disease) or suboptimal residual disease\r\n* All patients must have a procedure for determining diagnosis of epithelial ovarian, fallopian tube, primary peritoneal, with appropriate tissue for histologic evaluation\r\n* The minimum surgery required is an abdominal surgery providing tissue for histologic evaluation and establishing and documenting the primary site and stage, as well as a maximal effort at tumor debulking; if additional surgery was performed, it should have been in accordance with appropriate surgery for ovarian or peritoneal carcinoma described in the Gynecologic Oncology Group (GOG) Surgical Procedures ManualXx_NEWLINE_xXWoman diagnosed with ovarian, primary peritoneal or fallopian tube cancerXx_NEWLINE_xXHave had ovarian cancer or fallopian tube cancer at any ageXx_NEWLINE_xXNewly diagnosed with any stage of primary ovarian cancer, primary peritoneal cancer or primary fallopian tube cancer in the past 6 monthsXx_NEWLINE_xXovarian cancer: 2-4 prior treatmentsXx_NEWLINE_xXDiagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancerXx_NEWLINE_xXHistology showing high-grade epithelial non-mucinous ovarian, primary peritoneal, or fallopian tube cancerXx_NEWLINE_xXNo more than 4 prior cycles of chemotherapy for primary advanced (stage III or IV) epithelial ovarian, primary peritoneal, or fallopian tube cancerXx_NEWLINE_xXHistology showing mucinous or low grade epithelial ovarian carcinomaXx_NEWLINE_xXHistologically confirmed peritoneal carcinomatosis from appendiceal, colorectal, ovarian, or primary mesothelioma, with no systemic metastasesXx_NEWLINE_xXPatients with an initial diagnosis of ovarian, fallopian tube or primary peritoneal cancer who completed primary ovarian cancer surgery or 3 cycles of neoadjuvant chemotherapy with interval cytoreductive surgery (ICS)Xx_NEWLINE_xXFinal pathologic diagnosis of stage I-IV ovarian, primary peritoneal or fallopian tube cancer with plan to receive primary adjuvant chemotherapy or completion of chemotherapy after ICSXx_NEWLINE_xXPatients with recurrent ovarian cancer receiving chemotherapyXx_NEWLINE_xXUndergoing surgical management for a suspected diagnosis of gynecologic malignancy (endometrial, ovarian, vulvar, vaginal, primary peritoneal, fallopian tube)Xx_NEWLINE_xXWomen who have been newly diagnosed with a first primary, epithelial ovarian cancer, have undergone surgical debulking and who will be treatment according to the Armstrong methodXx_NEWLINE_xXNewly diagnosed, primary, epithelial ovarian cancerXx_NEWLINE_xXHave one relative with ovarian cancerXx_NEWLINE_xXPersonal history of ovarian cancerXx_NEWLINE_xXPatients with any stage epithelial ovarian cancer, including cancers arising from the fallopian tube and primary peritoneal cancer, or patients with other gynecologic malignancy (any stage), who are chemotherapy-naive, and scheduled to undergo at least 6 cycles of intravenous platinum/taxane-based chemotherapyXx_NEWLINE_xXPatients with a histological diagnosis of epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma, clinical stage II, III or IV at diagnosisXx_NEWLINE_xXPatients with a histological diagnosis of clinical stage I epithelial ovarian cancer, fallopian tube or primary peritoneal carcinomaXx_NEWLINE_xXPatients who are currently undergoing treatment (primary or consolidation) for stage II, III or IV ovarian, fallopian tube or primary peritoneal cancer or who completed treatment less than six weeks agoXx_NEWLINE_xXWomen with a personal history of ovarian, fallopian tube, or primary peritoneal cancerXx_NEWLINE_xXHistory of ovarian cancerXx_NEWLINE_xXOvarian cancer:Xx_NEWLINE_xXPresence of at least one fallopian tube; prior tubal ligation is allowedXx_NEWLINE_xXWomen with a history of ovarian, fallopian tube, or primary peritoneal cancerXx_NEWLINE_xXPatient must have epithelial ovarian, fallopian tube, or primary peritoneal cancer; this includes high-grade serous ovarian cancer, endometroid, clear cell, mixed epithelial, undifferentiated carcinoma, transitional cell carcinoma histologies\r\n* Patients with carcinosarcoma, non-epithelial, low grade tumors, or tumors with low malignant potential are excludedXx_NEWLINE_xXHistory of ovarian cancerXx_NEWLINE_xXAdult patients who have a presumed diagnosis of advanced stage epithelial ovarian, fallopian tube, or peritoneal\r\n* Pelvic mass and/or omental caking with Ca-125:carcinoembryonic antigen (CEA) ratio 25:1Xx_NEWLINE_xXNo prior treatment for ovarian cancerXx_NEWLINE_xXSubjects with a current diagnosis of epithelial ovarian tumor of low malignant potential (borderline carcinomas) are not eligibleXx_NEWLINE_xXEpithelial ovarian cancer, including fallopian tube cancer or primary peritoneal cancer, of high-grade serous histology, with platinum refractory or resistant disease after prior treatment with at least one platinum-based chemotherapeutic regimen. In Part B (dose expansion), subjects may have received no more than 3 lines of systemic cytotoxic chemotherapy.Xx_NEWLINE_xXEpithelial ovarian cancer which is contained within the abdomen, but may include pleural effusion if that is the limit of non-peritoneal cavity disease. If subject has recurrent epithelial ovarian cancer, the disease must be platinum sensitive (recurrence >6 months from prior chemotherapy regimen that included a platinum agent and cytoreductive surgery)Xx_NEWLINE_xXEpithelial ovarian cancer outside of the peritoneal cavity, with the exception of pleural effusionsXx_NEWLINE_xXPatients with presumed advanced-stage high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma, based on the presence of carcinomatosis, and/or elevated cancer antigen (CA)125, and/or ovarian mass(es), or at the discretion of the treating physicianXx_NEWLINE_xXNo prior therapy for high-grade serous ovarian, fallopian tube, or primary peritoneal carcinomaXx_NEWLINE_xXPrior treatment for ovarian, fallopian tube, or primary peritoneal cancerXx_NEWLINE_xXBIODISTRIBUTION COHORT: History of known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer (may have primary or metastatic cancer at the time of study enrollment)Xx_NEWLINE_xXDYNAMIC COHORT: History of known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer (may have primary or recurrent cancer at the time of study enrollment)Xx_NEWLINE_xXPatients must be suspected of having a diagnosis of ovarian, fallopian tube or primary peritoneal cancer with a planned cytoreductive surgeryXx_NEWLINE_xXHistologic diagnosis of epithelial ovarian, fallopian tube or primary peritoneal cancer confirmed on frozen section diagnosis during debulking surgeryXx_NEWLINE_xXNon-epithelial ovarian cancer or metastatic cancer from another site to the ovariesXx_NEWLINE_xXBorderline ovarian cancer without ascitesXx_NEWLINE_xXStudy Arm 2: Patients previously diagnosed with a non-mucinous epithelial ovarian carcinoma (including serous, clear cell, and endometrioid histologies as well as borderline ovarian tumors) currently undergoing routine surveillance for recurrence, having been diagnosed with recurrence but prior to initiation of chemotherapy; patients from Study Arm 1 will automatically be included in Study Arm 2 as well unless they withdraw consent; finally, patients who have been diagnosed with an ovarian cancer of acceptable histology, who have already undergone surgery or biopsy, but not yet initiated adjuvant chemotherapy are eligible for Study Arm 2Xx_NEWLINE_xXPatients with presumed advanced-stage high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma, based on the presence of carcinomatosis, and/or elevated cancer antigen 125 (CA125), and/or ovarian mass(es), or at the discretion of the treating physicianXx_NEWLINE_xXNo prior therapy for high-grade serous ovarian, fallopian tube, or primary peritoneal carcinomaXx_NEWLINE_xXPrior treatment for ovarian, fallopian tube, or primary peritoneal cancerXx_NEWLINE_xXFemale patients 18 years of age and older 2. Have a primary diagnosis, or at high clinical suspicion, of primary ovarian cancer (of epithelial type), planned for primary surgical cytoreduction, interval debulking, or have recurrent ovarian cancer surgery, and:Xx_NEWLINE_xXEpithelial ovarian cancer (including primary peritoneal disease and/or fallopian tube carcinomas and/or endometrial adenocarcinomas).Xx_NEWLINE_xXHave a primary diagnosis, or at high clinical suspicion, of primary ovarian cancer (of epithelial type), planned for primary debulking or interval debulking surgery, and:Xx_NEWLINE_xXHistologically confirmed Epitheilial Ovarian Cancer (EOC), Fallopian Tube Cancer (FTC) or Primary Peritoneal Cancer (PPC).Xx_NEWLINE_xXNon-epithelial ovarian cancers, including malignant mixed Müllerian tumors.Xx_NEWLINE_xX